Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-26T16:42:17.692Z Has data issue: false hasContentIssue false

EPA-0294 – Can Alpha 1 Glycoproptein be Considered as a Marker of Negative Symptoms in Schizophrenia Patients?

Published online by Cambridge University Press:  15 April 2020

M. Henry-Benitez
Affiliation:
Department of Internal Medicine Dermatology and Psychiatry, School of Medicine, Santa Cruz de Tenerife, Spain
A. Morera-Fumero
Affiliation:
Department of Internal Medicine Dermatology and Psychiatry, School of Medicine, Santa Cruz de Tenerife, Spain
A. Henry-Gonzalez
Affiliation:
UDMFyC, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
A. Garcìa-Hernandez
Affiliation:
Plastic and Cosmetic Surgery Facility, Hospital Quirón, Santa Cruz de Tenerife, Spain
L. Fernandez-Lopez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
E. Diaz-Mesa
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
S. Yelmo-Cruz
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
C. Casariego-Ramìrez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
N. Suarez-Benitez
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
R. Gracia-Marco
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
J. Monzon-Diaz
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain
J.P. Girbau-Ronda
Affiliation:
Department of Psychiatry, University Hospital of the Canary Islands, Santa Cruz de Tenerife, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction:

Recently, a renaissance of interest in ‘negative symptoms’ as emotional withdrawal or blunted affect, has occurred. Some investigators believe that these symptoms are important indicators of outcome, of response to treatment and of a distinct underlying pathologic process.

Research on the negative-symptom syndrome in schizophrenia has been handicapped until recently.

Aims:

This research aims at studying whether acute phase proteins, precisely, Alpha1-glycoprotein, can be considered as a marker of negativesymptom in Schizophrenia.

Methods:

29 chronic schizophrenics were assessed by the Positive and Negative Syndrome Scale (PANSS). A routine blood test including Alpha1-glycoprotein levels was carried out.

Results:

Alpha1-glycoprotein shows a positive correlation, according to Pearson correlation coefficient, with the Negative Scale at an almost significant level (p=.05), and at a significant level in the following items, Blunted affect (p=.03), Passive/apathetic Social Withdrawal (p=.01) of the Negative spectrum and Poor Attention (p=.02) of the General Psychopathology Scale.

Conclusions:

There is a significant correlation with two Negative variables and an almost significant one, spite of the small sample, with the Negative Scale. Further studies with bigger samples are needed in order to consider alpha1-glycoprotein as a schizophrenia negative psychopathology marker.

Type
EPW01 - Schizophrenia 1
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.